Alumis Inc. (ALMS) · Aug 13, 2026 · Earnings

Promising psoriasis data cannot hide a sharp revenue miss and pipeline write-down

Miss — Revenue $1.7M vs ~$4.1M consensus

ONWARD3 strengthens the psoriasis case, but revenue falls far short of consensus and Alumis writes down lonigutamab while preserving its 2027 cash runway.

The financial print missed the market's bar. Revenue was only $1.7 million, versus a published consensus near $4.1 million, with no license revenue in the quarter; the filing does not provide EPS, so an EPS comparison cannot be made.

MetricQ2 2026Q2 2025 / referenceMarket expectation
Total revenue$1.7M (Financial Results)$2.7M (Income Statement)~$4.1M consensus
R&D expense$85.3M (Financial Results)$108.8M (Income Statement)—
G&A expense$23.4M (Financial Results)$34.5M (Income Statement)—
Lonigutamab impairment$41.8M (Financial Results)$0 (Income Statement)—
Net loss$142.2M (Financial Results)$59.3M net income (Income Statement)—
Cash, cash equivalents and marketable securities$502.3M (Financial Guidance)—Runway into Q4 2027

The psoriasis dataset is the main offset, but not a clean surprise. ONWARD3 showed 75% of patients reaching PASI 90 and 54% reaching complete skin clearance after up to 48 weeks in 773 patients, with a safety profile described as consistent with earlier trials (ONWARD3). That supports the commercial and regulatory case, but the company had already reported positive pivotal Phase 3 ONWARD1 and ONWARD2 topline results in January 2026, making this more confirmation and durability detail than a wholly new thesis reset (ONWARD3).

The pipeline was narrowed, not simply expanded. Alumis remains on track for a psoriasis NDA submission in Q4 2026 and expects potentially pivotal SLE data in Q3 2026 (Anticipated 2026 Milestones). At the same time, it is exploring strategic alternatives for lonigutamab and recorded a $41.8 million impairment tied to that program (TYK2 Franchise and Pipeline Update; Financial Results). That write-down removes value from a non-core asset and signals sharper capital discipline, but also confirms the pipeline is becoming more dependent on envudeucitinib.

Cash buys time, not validation. The $502.3 million liquidity position and stated runway into Q4 2027 reduce near-term financing pressure (Financial Guidance). Net, however, the revenue miss and lonigutamab impairment outweigh the supportive psoriasis durability data because the clinical milestones were largely anticipated and the filing did not introduce a new financial catalyst.

What to watch next

LUMUS SLE topline data, Q3 2026

Original filing on SEC EDGAR

More Alumis Inc. news

Promising psoriasis data cannot hide a sharp revenue miss and pipeline write-down | ALMS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.